Peripheral blood lymphocyte subsets are associated with the clinical outcomes of prostate cancer patients

Mao, Fei; Yang, Chao; Luo, Wei; Wang, Yijin; Xie, Jie; Wang, Hengbin

doi:10.1016/j.intimp.2022.109287

Cited by 11 publications

(10 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The total T lymphocytes included Helper Inducer T lymphocytes (CD3+CD4+) and Suppressor Cytotoxic T lymphocytes (CD3+CD8+). Kaplan-Meier analysis in our study showed that patients with higher total CD3(+) T cells and CD3(+)CD4(+) T cells counts exhibited better survival, and the same results were demonstrated in other studies with cancer advancing (3,10,(15)(16)(17). It is worth mentioning that we further studied the CD4(+)/CD8(+) ratio and found a signi cantly decreased CD4(+)/CD8(+) ratio in nonsurvivors.…”

Section: Discussionsupporting

confidence: 89%

“…A lot of researchers focused on the relationship between the immune function and prognosis of cancer in recent years. B cells in the peripheral blood of patients with gastric cancer played an antitumor role by regulating their own functions to release in ammatory factors to inhibit T cells and NK cells (10) (17). These data may indicate that the function of NK cells was weakened in cancer patients, associating with the occurrence and progression of tumor.…”

Section: Discussionmentioning

confidence: 94%

“…. And recently, Mao et al reported that peripheral lymphocytes were associated with the survival of PC patients in a cohort, indicating that lower NK cells and lower CD4(+) T cells were unfavorable factor but the total B cells had no effect on prognosis (17). In our study, we further analyzed CD19(+)CD5(+) B lymphocytes and CD19(+)…”

mentioning

confidence: 83%

See 2 more Smart Citations

Circulating lymphocytes in Relation to Long-term Clinical Outcome in Patients with Prostate Cancer

Chen

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: The clinical outcomes of prostate cancer (PC) may involve changes in immune profiles. Whether long-term prognosis of PC is related to circulating lymphocytes is still uncertain. Therefore, we investigated the long-term prognostic value of different lymphocyte populations in PC. Materials: Patients with a pathological diagnosis of PC, at the Gleason Grades of 5 to 10 were included in the prospective cohort study. Lymphocyte count was evaluated in peripheral blood by flow cytometry. The prognostic value of different lymphocytes was analyzed in the whole cohort and the Kaplan-Meier method and Cox regression models were used for survival curves and multivariate analysis, respectively. Results: Between January 2001 and June 2021, 94 evaluable patients with prostate cancer were prospectively enrolled. The median follow-up duration of the study was 98 months. The levels of the CD4(+)/CD8(+) ratio, CD19(+), and CD19(+)CD5(−) B lymphocytes in non-survivors were lower than those in survivors. Grouping by each cutoff point of the lymphocytes respectively, the lower level of total CD3(+) T cells, CD3(+)CD4(+) T cells, the CD4(+)/CD8(+) ratio, total CD19(+) B cells, CD19(+)CD5(+) B cells, CD19(+)CD5(-) B cells showed poor survival. Multivariate Cox regression analysis confirmed the worse prognosis associated with higher PSA (HR=2.493, 95%CI: 1.356-4.584, P=0.003), lower CD3(+)CD4(+) T lymphocytes (HR=0.379, 95%CI: 0.170-0.843, P=0.017), lower total CD19(+) B cell (HR=0.398, 95%CI:0.187-0.845, P=0.016) and higher CD3(-)CD16(+)CD56(+) NK cells(HR=2.355, 95%CI: 1.175-4.723, P=0.016). Conclusion: Our results showed that low level of CD4(+) T lymphocytes, decreased CD19(+) B cell and high level of NK cells were correlated with poor survival, which indicates that B lymphocytes, CD4(+) T lymphocytes and NK cells might involve in prostate cancer and associated with the long-term prognosis of this elderly patients.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionmentioning

confidence: 94%

See 1 more Smart Citation

Circulating lymphocytes in Relation to Long-term Clinical Outcome in Patients with Prostate Cancer

Chen

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…The detection of low helper T lymphocyte levels can additionally contribute to the decision of active surveillance, radiotherapy, or surgery. Recently, Mao et al 16 evaluated peripheral blood lymphocyte subtypes and clinical outcomes of 135 prostate cancer patients and reported that an absolute CD4 T lymphocyte count of less than 255/μL is an unfavorable prognostic factor for prostate cancer survival. However, the remarkable part of the study is that only 35 patients underwent surgery and 72 patients were in the metastatic stage.…”

Section: Discussionmentioning

confidence: 99%

The Relationship Between Lymphocyte Subtypes with Clinicopathological Features and Prognosis of Prostate Cancer in Patients Undergoing Radical Prostatectomy

Sendogan,

Turan,

Erman

et al. 2023

Urology Research & Practice

View full text Add to dashboard Cite

Objective: The immune system has an essential role in the development of cancer by showing both anti-tumor and pro-tumor activities. Understanding the immune function of patients with malignancy is of clinical importance for the evaluation, treatment, and prognosis of the disease. We aimed to evaluate lymphocyte subtypes in peripheral blood samples of prostate cancer patients and their relationship with clinicopathological features and prognosis. Methods: One hundred thirty-seven patients who underwent open radical prostatectomy were included in our study. The percentages of CD3+T lymphocyte, CD19+ B lymphocyte, CD16/56 natural killer cells, CD4+ helper T lymphocyte, CD8+ cytotoxic T lymphocyte, and CD45 total lymphocyte were evaluated for each patient using the blood sample taken into a hemogram tube before surgery. Results: The pathological stage was T2 for 64 of the cases and T3 for 73. The mean follow-up period of the patients was 12.81 ± 6.20 months. The CD3+/CD4+ counts of the patients with pathological stage T2 were found to be statistically significantly higher than stage T3. There was a statistically significant negative correlation between the prostate-specific antigen levels and CD3+/CD4+ percentages of the patients. There was no statistical significance between the percentages of lymphocyte subtypes and the presence of surgical margin, biochemical recurrence, adjuvant therapy, and cancer upgrade. Conclusion: We consider that the increase in the pathological stage and prostate-specific antigen value and the decrease in the number of CD4+ T lymphocyte subtypes may be prognostic markers in prostate cancer patients.

show abstract

“…When there is an inadequate number of effective lymphocytes, the combination of anti-PD-1/PD-L1 therapy may not benefit cancer patients ( 20 ). Therefore, detecting dynamic changes in lymphocyte subsets is of great significance for early efficacy prediction, decisions on the replacement of ineffective treatments, the timely utilization of immunotherapy and the timely application of lymphocyte-improving drugs, such as thymosin in the clinic ( 21 , 22 ).…”

Section: Introductionmentioning

confidence: 99%

Dynamic surveillance of lymphocyte subsets in patients with non-small cell lung cancer during chemotherapy or combination immunotherapy for early prediction of efficacy

Zhen,

Wang,

Qin

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

BackgroundNon-small cell lung cancer (NSCLC) remains the leading cause of cancer-related deaths worldwide. Lymphocytes are the primary executors of the immune system and play essential roles in tumorigenesis and development. We investigated the dynamic changes in peripheral blood lymphocyte subsets to predict the efficacy of chemotherapy or combination immunotherapy in NSCLC.MethodsThis retrospective study collected data from 81 patients with NSCLC who received treatments at the First Affiliated Hospital of Zhengzhou University from May 2021 to May 2023. Patients were divided into response and non-response groups, chemotherapy and combination immunotherapy groups, and first-line and multiline groups. We analyzed the absolute counts of each lymphocyte subset in the peripheral blood at baseline and after each treatment cycle. Within-group and between-group differences were analyzed using paired Wilcoxon signed-rank and Mann-Whitney U tests, respectively. The ability of lymphocyte subsets to predict treatment efficacy was analyzed using receiver operating characteristic curve and logistic regression.ResultsThe absolute counts of lymphocyte subsets in the response group significantly increased after the first cycle of chemotherapy or combination immunotherapy, whereas those in the non-response group showed persistent decreases. Ratios of lymphocyte subsets after the first treatment cycle to those at baseline were able to predict treatment efficacy early. Combination immunotherapy could increase lymphocyte counts compared to chemotherapy alone. In addition, patients with NSCLC receiving chemotherapy or combination immunotherapy for the first time mainly presented with elevated lymphocyte levels, whereas multiline patients showed continuous reductions.ConclusionDynamic surveillance of lymphocyte subsets could reflect a more actual immune status and predict efficacy early. Combination immunotherapy protected lymphocyte levels from rapid decrease and patients undergoing multiline treatments were more prone to lymphopenia than those receiving first-line treatment. This study provides a reference for the early prediction of the efficacy of clinical tumor treatment for timely combination of immunotherapy or the improvement of immune status.

show abstract

Peripheral blood lymphocyte subsets are associated with the clinical outcomes of prostate cancer patients

Cited by 11 publications

References 50 publications

Circulating lymphocytes in Relation to Long-term Clinical Outcome in Patients with Prostate Cancer

Circulating lymphocytes in Relation to Long-term Clinical Outcome in Patients with Prostate Cancer

The Relationship Between Lymphocyte Subtypes with Clinicopathological Features and Prognosis of Prostate Cancer in Patients Undergoing Radical Prostatectomy

Dynamic surveillance of lymphocyte subsets in patients with non-small cell lung cancer during chemotherapy or combination immunotherapy for early prediction of efficacy

Contact Info

Product

Resources

About